Biotech sector performance has re-accelerated, driven by M&A and clinical updates, with the portfolio outperforming the index due to key holdings. Increased investment activity and an AI-driven operating system are enhancing productivity, while upcoming U.S. elections are seen as a sector catalyst.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.